Clinical trial NCT03109886: Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
Official title: Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Keywords: Unresectable Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma
Child-Pugh Class A
Lead sponsor: Tiziana Life Sciences LTD
Sponsor class: INDUSTRY
First posted: 2017-04-12
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary aim of this exploratory study is to test the safety and tolerability of milciclib when administered orally at 100 mg in patients with recurrent or metastatic Hepatocellular Carcinoma. The evaluation of the efficacy profile is a secondary objective of the study. Moreover, markers expression in tumor cells and plasma will be studied and described in association with the clinical outcome.

Eligible patients will receive milciclib orally on a daily schedule for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier.

At the end of Cycle 3, treatment will be stopped, and based on the results of the tumor assessment performed on Day 90 (±3 days) from treatment start, patients will be followed as here below detailed:

* patients with Complete Response (CR)/Partial Response (PR)/Stable Disease (SD) will be followed for safety until 30 days from last dose intake (or until a new anticancer therapy starts, whichever occurs earlier) and will be assessed for efficacy in the follow-up period up to Day 180 from treatment start;
* patients with progressive disease will be followed only for safety until 30 days from last dose intake (or until a new anticancer therapy starts, whichever occurs earlier).

After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.


Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of HCC, confirmed by histology or radiology according to American Association for the Study of Liver Diseases/European Association for the Study of the Liver (AASLD/EASL) criteria prior to the start of the investigational product. Imaging characteristics should be retrieved from at least a 3-phase liver protocol CT or MRI with target tumor lesion(s) demonstrating arterial hyper-enhancement and wash-out in the venous phase;
* Tumor stages eligible for the study are defined as:

  1. HCC within the Barcelona Clinic Liver Cancer (BCLC) stage C. In case of portal vein thrombosis (PVT) an associated target lesion in the liver parenchyma should be clearly defined. PVT without associated target lesion are not eligible to the study;
  2. Untreatable post-chemoembolization (TACE) or post-radioembolization (TARE) progression defined as BCLC stage B or C with radiographic progression according to mRECIST after TACE or TARE not eligible for further surgical or loco-regional therapy;
  3. Recurring HCC non eligible for pre-transplant downstaging protocols or for resection;
* Patients must have failed sorafenib treatment or be intolerant to sorafenib or actively refusing sorafenib

  1. Failing sorafenib treatment is defined if after ≥ 14 days of therapy (not necessarily consecutive) radiology progression is ascertained according to mRECIST;
  2. Intolerant to sorafenib treatment is defined as a sorafenib related Grade 2 or greater adverse event (CTC-AE) that continues or recurs after sorafenib treatment interruption for 7 days or dose reduction;
  3. Active refusal should be documented by a written and signed patient declaration to be filed in the clinical records;
* Child-Pugh score ≤ 6 (class A);
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
* Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radioembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks prior to study entry with documentation of progressive or recurrent disease;
* Signed and dated Investigational Review Board/Independent Ethics Committee (IRB/IEC) approved Informed Consent/Genetic Consent.

Exclusion Criteria:

* Prior use of any systemic anti-cancer therapy (including experimental agents and immunotherapy) except for sorafenib and second line treatment with regorafenib discontinued for intolerance within 14 days;
* Known fibrolamellar HCC or mixed hepato-cholangiocarcinoma;
* Grade 3 oesophageal varices, regardless of previous bleeding episodes on endoscopy performed no more than in the last 12 months;
* Clinical meaningful ascites defined as CTCAE Grade≥2. Patient who have been on a stable medication regimen for at least 2 months to manage ascites are eligible if they show no ascites at the clinical examination. Patients with clinically undetectable ascites who are Child A with detectable ascites at CT/MRI are eligible to the protocol;

Primary outcomes:
measure: Overall Safety Profile
timeFrame: From Informed Consent signature to 30 days after last dose intake up to Day 180 from treatment start
Secondary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: At screening; During treatment at Day 45 and 90; During follow up at Day 180 for patients not progressed at previous assessments
measure: Objective Response Rate (ORR)
timeFrame: At screening; During treatment at Day 45 and 90; During follow up at Day 180 for patients not progressed at previous assessments
measure: Progression-Free Survival (PFS)
timeFrame: From treatment start to date of progression assessed on Day 45, 90 or 180 or to date of death if before day 180
measure: Time to Progression (TPP)
timeFrame: From treatment start to date of progression assessed on Day 45, 90 or 180 or to date of death if before day 180
measure: TPP-3 months
timeFrame: Based on tumor assessment at or after 3 months from treatment start
measure: Duration of overall Response (DoR)
timeFrame: Based on assessments performed on Day 45, 90 or 180 or date of death if before day 180
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Ippokrateio General Hospital of Athens
city: Athens
country: Greece
facility: Laiko General Hospital of Athens
city: Larissa
country: Greece
facility: General University Hospital of Larissa
city: Thessaloniki
country: Greece
facility: University General Hospital of Thessaloniki - AHEPA
city: Haifa
country: Israel
facility: Rambam Health Corporation
city: Petah Tikva
country: Israel
facility: Rabin Medical Center - Beilinson Hospital
city: Ramat Gan
country: Israel
facility: The Sheba Academic Medical Center Hospital - Tel Hashomer
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas
state: MI
city: Bologna
country: Italy
facility: AOU S. Orsola Malpighi Bologna
city: Milano
country: Italy
facility: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
city: Modena
country: Italy
facility: Azienda Ospedaliera Universitaria Policlinico di Modena
city: Napoli
country: Italy
facility: A.O.U. Federico II
city: Palermo
country: Italy
facility: A.O. U. Policlinico Paolo Giaccone
Study officials:
affiliation: Tiziana Life Sciences LTD
name: Fayez M Hamzeh, MD
role: STUDY_CHAIR
affiliation: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico - Milano, Italy
name: Angelo Sangiovanni, MD, PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: Istituto Clinico Humanitas - Rozzano (MI), Italy
name: Armando Santoro, MD
role: PRINCIPAL_INVESTIGATOR
References: